Eagle Pharmaceuticals price target raised to $30 from $22 at Cantor Cantor said Ryanodex, which Eagle Pharmaceuticals has priced significantly above the firm's initial expectations, is planned to launch at the end of this month and should help offset some of the losses associated with argatroban. The firm raised its price target on Eagle to $30 from $22 and reiterates its Buy rating on the shares.
Eagle Pharmaceuticals price target raised to $119 from $94 at Piper Jaffray Piper Jaffray analyst David Amsellem raised his price target for Eagle Pharmaceuticals (EGRX) to $119 after analyzing the company's bendamustine products, which are enhanced forms of Teva's (TEVA) Treanda. Amsellem believes there could be "considerable upside" to his current earnings estimates for Eagle. The company's agreement with Teva provides "almost ironclad downside protection, and leaves ample room for upside," he tells investors in a research note. Further, he sees limited potential for generic entrants on Teva's forms of Treanda for the foreseeable future. Amsellem reiterates an Overweight rating on Eagle Pharmaceuticals.